dBio Appoints Hubertus ‘Bert’ Hoyt as Board Advisor
LUXEMBOURG, April 24, 2025 — Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), a pioneer in sports and health technology, has announced the appointment of Hubertus ‘Bert’ Hoyt as its newest Board Advisor. With over 32 years of experience in the sports industry, Bert brings invaluable strategic insights to dBio’s Board, supporting its mission to revolutionize personalized healthcare and fitness technologies worldwide.
Revolutionizing Health and Exercise Management
dBio empowers individuals to better understand their bodies through advanced wearable AIoT solutions, optimizing training, accelerating recovery, and reducing injury risk with personalized, data-driven feedback. The company’s proprietary technologies include gMOTCloud, an AI-powered kinesiology wearable that captures detailed motion and gait metrics, and StethoCloud, a lightweight wearable stethoscope enabling continuous heart and respiratory monitoring with AI-enhanced noise reduction. These devices offer cloud-based analytics and virtual coaching support for healthier, safer, and more effective exercise performance.
With more than 75 registered patents and a fully self-developed ecosystem spanning AI modeling, hardware, software, and app development, dBio delivers a comprehensive solution for performance optimization and health management. This solution caters to a wide range of users, from elite athletes to fitness enthusiasts, and has applications in telemedicine, rehabilitation, and elder care. dBio’s technology is supported by strategic partnerships with leaders across the medical, academic, and athletic sectors.
Bert Hoyt: A Proven Innovator in Global Brand Building
Bert began his career in 1989 at Puma, rising through the ranks from product management to business leadership. He later served as General Manager of Puma International, driving the company’s growth between 1992 and 1998. In 1998, Bert joined Nike, where he spent 22 years as a senior executive, holding various leadership roles including Vice President & General Manager of Nike Western Europe and EMEA. Under his leadership, Nike Western Europe grew from US$3 billion to US$7 billion, with EMEA reaching over US$10 billion in revenue and achieving a 24% EBIT.
Bert is known for his deep understanding of consumer needs and his ability to align teams to a clear consumer vision. Since retiring from Nike in early 2021, Bert has served as a non-executive Director at several companies, including JD Sports PLC and Cosnova GmbH. A former ATP tennis professional, Bert competed from 1977 to 1984.
“I’ve been involved in helping athletes improve their performance throughout my personal and business life. I’m joining dBio because I believe their innovations will be the next chapter in athlete performance and provide sports enthusiasts with precise data to improve their overall well-being,” Bert said.
As dBio continues to expand its global footprint, it aims to redefine the future of personalized health and performance technology with Bert Hoyt on board.
